PBAC's latest decision on Chlormethine hydrochloride: Recommended with restriction (2023). Considered for Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients with no more than 25% body surface area involved, who have failed, are intolerant of, or have a contraindication to topical corticosteroids.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2023
Submissions
2
2023 → 2023
Eligible population
Adult patients with stage IA, IIA, or IB mycosis fungoides-type cutaneous T-cell lymphoma with no more than 25% body surface area involvement, confirmed by diagnostic lesion biopsy, who have failed or are intolerant/contraindicated to topical corticosteroids.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
Single-arm
Primary endpoint
Restricted mean duration of complete response
Key trials
Study 201
Comparator
phototherapy (PUVA and UVB)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design
Submission history
Mar 2023: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required